Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts have updated their price targets and ratings for several companies, including Atossa Therapeutics, Novartis, Camden National, Supernus Pharmaceuticals, AppLovin, Krystal Biotech, Dave & Buster's, GameStop, Academy Sports, and Domino's Pizza. These changes reflect varying outlooks on the companies' future performance.
September 11, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BMO Capital cut Domino’s Pizza's price target from $525 to $510, maintaining an Outperform rating. Shares fell 0.8%.
The reduced price target by BMO Capital suggests a less optimistic outlook, likely leading to a negative impact on the stock price despite the maintained Outperform rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Wedbush cut GameStop's price target from $11 to $10, maintaining an Underperform rating. Shares fell 3.3%.
The reduced price target and maintained Underperform rating by Wedbush indicate a negative outlook, likely leading to a further decline in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
B of A Securities cut Novartis' price target from $135 to $130 and downgraded the stock from Buy to Neutral. Shares fell 0.2%.
The downgrade and reduced price target by B of A Securities indicate a less optimistic outlook, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
BMO Capital cut Dave & Buster’s price target from $65 to $55, maintaining an Outperform rating. Shares fell 0.8%.
The reduced price target by BMO Capital suggests a less optimistic outlook, likely leading to a negative impact on the stock price despite the maintained Outperform rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Piper Sandler cut Supernus Pharmaceuticals' price target from $41 to $36, downgrading the stock from Overweight to Neutral. Shares fell 1.2%.
The downgrade and reduced price target by Piper Sandler indicate a less favorable outlook, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Keefe, Bruyette & Woods raised Camden National's price target from $40 to $41, maintaining a Market Perform rating. Shares fell 0.3%.
The slight increase in price target with a maintained Market Perform rating suggests a neutral outlook, with minimal short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
B of A Securities raised AppLovin's price target from $100 to $120, maintaining a Buy rating. Shares fell 0.1%.
The increased price target and maintained Buy rating by B of A Securities suggest positive sentiment, likely supporting the stock price despite the slight decline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Truist Securities boosted Academy Sports' price target from $60 to $63, maintaining a Buy rating. Shares gained 5.2%.
The increased price target and maintained Buy rating by Truist Securities suggest a positive outlook, likely contributing to the stock's significant gain.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Ascendiant Capital raised Atossa Therapeutics' price target from $6.25 to $6.5, maintaining a Buy rating. The stock gained 7.4% to close at $1.46.
The increase in price target and maintained Buy rating by Ascendiant Capital suggests positive sentiment, likely boosting investor confidence and driving the stock price up.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Stifel boosted Krystal Biotech's price target from $204 to $220, maintaining a Buy rating. Shares fell 1.4%.
The increased price target and maintained Buy rating by Stifel suggest a positive outlook, likely supporting the stock price despite the decline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80